Motixafortide: clinical trials recruiting now
3
Recruiting trials
4
Conditions studied
6
US states with sites
1
Countries
FDA drug label
- FDA-approved
- Yes. Motixafortide appears in the FDA drug-label database. Marketed as APHEXDA.
FDA-approved use
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )
Phase breakdown
Phase 1 2
Phase 2 1
Conditions being studied
| Condition | Trials |
|---|---|
| Sickle Cell Disease | 2 |
| Adenocarcinoma | 1 |
| Adenocarcinoma of the Pancreas | 1 |
| Pancreatic Cancer | 1 |
Recruiting trials involving Motixafortide
- Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
- Gene Editing For Sickle Cell Disease
- SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Common questions
Is Motixafortide FDA-approved?
Yes, marketed as APHEXDA.
How many recruiting trials involve Motixafortide?
3 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.